AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15102080 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human alpha‐galactosidase A (r‐halphaGalA) continued in open label extension study
Number of subjects: 58
Study 15102080 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human alpha‐galactosidase A (r‐halphaGalA)
Number of subjects: 58
Study 11563996 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine, 75 mg
Number of subjects: 994
Study 11563996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 994
Study 9351881 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical etidronate therapy
Number of subjects: 152
Study 9351881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 1562407 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-labeled polyclonal human immunoglobulin (IgG)
Number of subjects: 14
Study 1562407 — intervention group
Group type: EXPERIMENTAL
Intervention: 111In granulocytes
Number of subjects: 14
Study 2858749 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation by nasogastric intubation
Number of subjects: 5
Study 2858749 — intervention group
Group type: EXPERIMENTAL
Intervention: Nightly oral formula supplements
Number of subjects: 5
Study 2858749 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc, iron, folate, and vitamin E supplements
Number of subjects: 5
Study 30569776 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative pacing strategy in classic style
Number of subjects: 12
Study 30569776 — intervention group
Group type: EXPERIMENTAL
Intervention: Vmax and %Vmax
Number of subjects: 12
Study 30569776 — intervention group
Group type: EXPERIMENTAL
Intervention: Vmax to finish sprint
Number of subjects: 12
Study 29595685 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg
Number of subjects: 294
Study 29595685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 294
Study 27031055 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley catheter
Number of subjects: 202
Study 27031055 — intervention group
Group type: COMPARATOR
Intervention: Oral misoprostol
Number of subjects: 202
Study 25341145 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline with 0.9% benzyl alcohol (test group)
Number of subjects: 138
Study 25341145 — intervention group
Group type: COMPARATOR
Intervention: Preservative-free normal saline (control group)
Number of subjects: 138
Study 22592929 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg misoprostol vaginally 12 hours before hysteroscopy
Number of subjects: 55
Study 22592929 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cervical priming)
Number of subjects: 55
Study 20098847 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue Light treatment (8 times, twice a week)
Number of subjects: 60
Study 20098847 — intervention group
Group type: COMPARATOR
Intervention: Topical Benzoyl Peroxide 5% formulation (auto-applied twice a day, every day)
Number of subjects: 60
Study 17006433 — intervention group
Group type: COMPARATOR
Intervention: 5 mg THC
Number of subjects: 15
Study 15837967 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated accelerated radiation therapy (HART), 57.6 Gy (1.5 Gy tid for 2.5 weeks)
Number of subjects: 141
Study 15837967 — intervention group
Group type: COMPARATOR
Intervention: Once-daily radiation therapy (qdRT), 64 Gy (2 Gy/d)
Number of subjects: 141
Study 11880910 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous outcome variables
Number of subjects: 76
Study 11880910 — intervention group
Group type: COMPARATOR
Intervention: Dichotomous outcome variables
Number of subjects: 76
Study 9817169 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD‐IP
Number of subjects: 41
Study 9817169 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 41
Study 7716598 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen
Number of subjects: 18
Study 7716598 — intervention group
Group type: EXPERIMENTAL
Intervention: four-gas mixture (oxygen 21.0%, argon 48.6%, nitrogen 19.3%, helium 11.1%)
Number of subjects: 18
Study 7716598 — intervention group
Group type: COMPARATOR
Intervention: air
Number of subjects: 18
Study 2189950 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin, cyclophosphamide, and tamoxifen (ACT)
Number of subjects: 1124
Study 2189950 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin, fluorouracil, and tamoxifen (PAFT)
Number of subjects: 1124
Study 2189950 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan, fluorouracil, and tamoxifen (PFT)
Number of subjects: 1124
Study 2189950 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen alone (TAM)
Number of subjects: 1124
Study 116278 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam (UCB 6215, Nootropyl)
Number of subjects: 0
Study 31549577 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone, 50 mg orally once daily for 12 months
Number of subjects: 52
Study 31549577 — intervention group
Group type: COMPARATOR
Intervention: Eplerenone, 50 mg orally once daily for 12 months
Number of subjects: 52
Study 28686777 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical dapsone gel, 7.5%
Number of subjects: 4340
Study 28686777 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 4340
Study 24935984 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum neurofilament light chain (NfL) levels in motor-incomplete SCI (iSCI) patients
Number of subjects: 94
Study 24935984 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum neurofilament light chain (NfL) levels in motor-complete SCI (cSCI) patients
Number of subjects: 94
Study 24935984 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum neurofilament light chain (NfL) levels in central cord syndrome (CCS) patients
Number of subjects: 94
Study 24935984 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal measurement of serum NfL levels
Number of subjects: 94
Study 24935984 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of NfL levels with ASIA motor score
Number of subjects: 94
Study 24935984 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline treatment in cSCI patients
Number of subjects: 94
Study 24935984 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum NfL concentrations in SCI patients
Number of subjects: 94
Study 24935984 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood NfL levels
Number of subjects: 94
Study 23663063 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose (20 Gy) of Gamma knife radiosurgery
Number of subjects: 24
Study 23663063 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (24 Gy) of Gamma knife radiosurgery
Number of subjects: 24
Study 23663063 — intervention group
Group type: COMPARATOR
Intervention: Gamma knife radiosurgery (both doses)
Number of subjects: 24
Study 21889951 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (6 mg)
Number of subjects: 24
Study 19819042 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinitapride 1mg oral solution t.i.d for 4 weeks
Number of subjects: 19
Study 19819042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 19819042 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinitapride
Number of subjects: 19
Study 17289910 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic alkalosis (Alk)
Number of subjects: 8
Study 17289910 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Con)
Number of subjects: 8
Study 15326091 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (with possible combination or replacement by enalapril, hydrochlorothiazide, or both)
Number of subjects: 0
Study 15326091 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study 11684378 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg daily)
Number of subjects: 66
Study 9123945 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg oral dexibuprofen three times daily
Number of subjects: 110
Study 9123945 — intervention group
Group type: COMPARATOR
Intervention: 50 mg oral diclofenac sodium three times daily
Number of subjects: 110
Study 9123945 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dexibuprofen and diclofenac sodium
Number of subjects: 110
Study 7534166 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin 7.5 mg/day for 30 days
Number of subjects: 30
Study 7534166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 3058538 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupirtine maleate
Number of subjects: 40
Study 3058538 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium
Number of subjects: 40
Study 31618498 — intervention group
Group type: EXPERIMENTAL
Intervention: Ointment containing Ceratothoa oestroides extract
Number of subjects: 52
Study 31618498 — intervention group
Group type: EXPERIMENTAL
Intervention: Ointment containing Ceratothoa oestroides extract and eosin
Number of subjects: 52
Study 31618498 — intervention group
Group type: COMPARATOR
Intervention: Ointment containing Ceratothoa oestroides extract and cefaclor
Number of subjects: 52
Study 31618498 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 52
Study 31098654 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (n-3 PUFA) 2.2 g/day
Number of subjects: 71
Study 31098654 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 71
Study 31098654 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (n-3 PUFA)
Number of subjects: 71
Study 29069156 — intervention group
Group type: EXPERIMENTAL
Intervention: OTC non-hydrogen peroxide bleaching agent (iWhite Instant)
Number of subjects: 40
Study 29069156 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identically composed product without active agents)
Number of subjects: 40
Study 25425023 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronate administration after radiotherapy (Group A)
Number of subjects: 40
Study 25425023 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronate administration prior to radiotherapy (Group B)
Number of subjects: 40
Study 25425023 — intervention group
Group type: COMPARATOR
Intervention: Control group (radiotherapy only)
Number of subjects: 40
Study 22947179 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 576
Study 22947179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 576
Study 20009961 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE + progestogen (continuous or cyclical medroxyprogesterone acetate or cyclical micronized progesterone)
Number of subjects: 662
Study 20009961 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE alone
Number of subjects: 662
Study 20009961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 662
Study 20009961 — intervention group
Group type: EXPERIMENTAL
Intervention: Strenuous exercise
Number of subjects: 662
Study 20009961 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-Tocopherol intake, age, smoking, and alcohol intake
Number of subjects: 662
Study 18155215 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-trained endoscopists (skilled and trainee)
Number of subjects: 140
Study 18155215 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-trained endoscopists (trainee)
Number of subjects: 140
Study 18155215 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-trained endoscopists (skilled)
Number of subjects: 140
Study 18155215 — intervention group
Group type: EXPERIMENTAL
Intervention: Study patients
Number of subjects: 140
Study 18155215 — intervention group
Group type: EXPERIMENTAL
Intervention: Study patients with previous conventional EGD
Number of subjects: 140
Study 18155215 — intervention group
Group type: COMPARATOR
Intervention: Controls (endoscopist skilled in UT‐EGD)
Number of subjects: 140
Study 16148616 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (160 mg/day) administered at bedtime
Number of subjects: 148
Study 16148616 — intervention group
Group type: COMPARATOR
Intervention: Valsartan (160 mg/day) administered in the morning
Number of subjects: 148
Study 12680160 — intervention group
Group type: EXPERIMENTAL
Intervention: Marimastat 10 mg b.d. for up to two years
Number of subjects: 121
Study 12680160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 12680160 — intervention group
Group type: EXPERIMENTAL
Intervention: Marimastat with musculoskeletal symptoms
Number of subjects: 121
Study 12680160 — intervention group
Group type: EXPERIMENTAL
Intervention: Marimastat without musculoskeletal symptoms
Number of subjects: 121
Study 14590216 — intervention group
Group type: EXPERIMENTAL
Intervention: Coached Simulator group
Number of subjects: 92
Study 14590216 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncoached Simulator group
Number of subjects: 92
Study 14590216 — intervention group
Group type: COMPARATOR
Intervention: Control group (optimal performance)
Number of subjects: 92
Study 14590216 — intervention group
Group type: EXPERIMENTAL
Intervention: TBI patients
Number of subjects: 92
Study 14590216 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision rule of > 1 error on subtests I and II
Number of subjects: 92
Study 8829823 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 253
Study 1796656 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam (1 x 20 mg daily)
Number of subjects: 33
Study 1796656 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (2 x 50 mg daily)
Number of subjects: 33
Study 1796656 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (3 x 25 mg daily)
Number of subjects: 33
Study 6880546 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional intravenous sympathetic block with guanethidine (RGB)
Number of subjects: 34
Study 6880546 — intervention group
Group type: COMPARATOR
Intervention: Control group (no RGB)
Number of subjects: 34
Study 30883596 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate intake (0.2 g/kg every 15 minutes) during exercise with bananas (Cavendish, Mini-yellow) and a 6% sugar beverage
Number of subjects: 20
Study 30883596 — intervention group
Group type: COMPARATOR
Intervention: Water only (control)
Number of subjects: 20
Study 27177956 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesia iv exclusively (Group 1)
Number of subjects: 147
Study 27177956 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia + analgesia iv (Group 2)
Number of subjects: 147
Study 27177956 — intervention group
Group type: EXPERIMENTAL
Intervention: Port-sites infiltration + analgesia iv (Group 3)
Number of subjects: 147
Study 27177956 — intervention group
Group type: COMPARATOR
Intervention: Control group (Analgesia iv exclusively)
Number of subjects: 147
Study 27852723 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 1600
Study 27852723 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 1600
Study 24930202 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation exercises (walking, bicycle ergometry, resistance exercises), thrice-weekly for three weeks
Number of subjects: 30
Study 24930202 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study 22552429 — intervention group
Group type: EXPERIMENTAL
Intervention: U-grooved locking compression plate (U-LCP)
Number of subjects: 78
Study 22552429 — intervention group
Group type: COMPARATOR
Intervention: LISS
Number of subjects: 78
Study 20001426 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic cannabinoids (nabilone, dronabinol, combination of synthetic Delta9‐THC and cannabidiol)
Number of subjects: 0
Study 20001426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17295293 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching to aminoglutethimide or anastrozole after 2 or 3 years of tamoxifen therapy
Number of subjects: 828
Study 17295293 — intervention group
Group type: COMPARATOR
Intervention: Continuing tamoxifen for an additional 2 or 3 years
Number of subjects: 828
Study 17295293 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching to aminoglutethimide or anastrozole
Number of subjects: 828
Study 15766293 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 60
Study 15766293 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 60
Study 15766293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 11900215 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting release octreotide pamoate (OP-LAR) plus tamoxifen (TAM)
Number of subjects: 203
Study 11900215 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus tamoxifen (TAM)
Number of subjects: 203
Study 11900215 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting release octreotide pamoate (OP-LAR)
Number of subjects: 203
Study 12884888 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine maintenance treatment (n = 29)
Number of subjects: 56
Study 12884888 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of imipramine (n = 27)
Number of subjects: 56
Study 7838190 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 percent solution of povidone-iodine (n = 1076)
Number of subjects: 3117
Study 7838190 — intervention group
Group type: COMPARATOR
Intervention: 1 percent solution of silver nitrate (n = 929)
Number of subjects: 3117
Study 7838190 — intervention group
Group type: COMPARATOR
Intervention: 0.5 percent erythromycin ointment (n = 1112)
Number of subjects: 3117
Study 2323218 — intervention group
Group type: EXPERIMENTAL
Intervention: MLCu-250
Number of subjects: 34
Study 2323218 — intervention group
Group type: EXPERIMENTAL
Intervention: MLCu-375
Number of subjects: 34
Study 7350901 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline chloride (16 g)
Number of subjects: 0
Study 31422215 — intervention group
Group type: EXPERIMENTAL
Intervention: 980-nm/1470-nm dual-wavelength fiber laser surgery
Number of subjects: 44
Study 31422215 — intervention group
Group type: COMPARATOR
Intervention: CO2 laser surgery
Number of subjects: 44
Study 31422215 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study 28323625 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching Training (ST)
Number of subjects: 24
Study 28323625 — intervention group
Group type: COMPARATOR
Intervention: Control (no-exercise)
Number of subjects: 24
Study 23717423 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 220
Study 23717423 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (CQ)
Number of subjects: 220
Study 21652616 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel™ with standard Rüsch™ PVC tracheal tube
Number of subjects: 160
Study 21652616 — intervention group
Group type: COMPARATOR
Intervention: sILMA™ with single-use ILMA™ tracheal tube
Number of subjects: 160
Study 21652616 — intervention group
Group type: COMPARATOR
Intervention: sILMA™
Number of subjects: 160
Study 21652616 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel™ and sILMA™
Number of subjects: 160
Study 19367335 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated counseling (AA)
Number of subjects: 278
Study 19367335 — intervention group
Group type: COMPARATOR
Intervention: Standard counseling (SA)
Number of subjects: 278
Study 16550263 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA‐BDP
Number of subjects: 17
Study 16550263 — intervention group
Group type: EXPERIMENTAL
Intervention: DPI‐BUD
Number of subjects: 17
Study 16550263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 12670672 — intervention group
Group type: EXPERIMENTAL
Intervention: DMSO 50% applied five times daily to the affected extremity
Number of subjects: 146
Study 12670672 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600mg effervescent tablets three times daily
Number of subjects: 146
Study 12670672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 10749011 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive CD-ROM program designed to teach refusal skills and socially acceptable responses to substance use situations.
Number of subjects: 74
Study 10749011 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive CD-ROM program
Number of subjects: 74
Study 9192919 — intervention group
Group type: EXPERIMENTAL
Intervention: Active air-cleaners in living-rooms and bedrooms
Number of subjects: 45
Study 9192919 — intervention group
Group type: COMPARATOR
Intervention: Placebo air-cleaners with allergen-impermeable mattress covers
Number of subjects: 45
Study 9192919 — intervention group
Group type: EXPERIMENTAL
Intervention: Active air-cleaners with allergen-impermeable mattress covers
Number of subjects: 45
Study 9192919 — intervention group
Group type: EXPERIMENTAL
Intervention: Active air-cleaners
Number of subjects: 45
Study 8466740 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (2.5 mg twice daily)
Number of subjects: 25
Study 8466740 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (20 mg twice daily)
Number of subjects: 25
Study 3809112 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone administered to pregnant women
Number of subjects: 5
Study 3809112 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 5
Study 29493875 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment (oxygen, corticosteroids, bronchodilators, physiotherapy) plus one session of sophrology
Number of subjects: 74
Study 29493875 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 74
Study 27650009 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated palliative and respiratory care service
Number of subjects: 20
Study 24794477 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 80
Study 24794477 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 80
Study 22077562 — intervention group
Group type: EXPERIMENTAL
Intervention: Alutard SQ, Phleum pratense 100,000 SQ‐U, 10,000 SQ‐U
Number of subjects: 221
Study 22077562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study 19788592 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime supine posture (DSP) study
Number of subjects: 25
Study 19004402 — intervention group
Group type: EXPERIMENTAL
Intervention: Feminine hygiene wet wipes for 28 days
Number of subjects: 180